Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06544733
PHASE2/PHASE3

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Sponsor: Gilead Sciences

View on ClinicalTrials.gov

Summary

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182 with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY), to see if the combination of GS-1720 and GS-4182 is safe and if it works for treating human immunodeficiency virus type 1 (HIV-1) infection. This study has two phases: Phase 2 and Phase 3. The primary objectives of this study are: Phase 2: To evaluate the efficacy of switching to oral weekly GS-1720 in combination with GS-4182 versus continuing BVY in virologically suppressed people with HIV-1 (PWH) at Week 24. Phase 3: To evaluate the efficacy of switching to oral weekly GS-1720/GS-4182 Fixed-dose combination (FDC) tablet regimen versus continuing BVY in virologically suppressed PWH at Week 48.

Official title: An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

675

Start Date

2024-08-20

Completion Date

2029-06

Last Updated

2026-01-05

Healthy Volunteers

No

Conditions

Interventions

DRUG

GS-1720

Tablets administered orally without regard to food

DRUG

GS-4182

Tablets administered orally without regard to food

DRUG

Placebo to Match BVY

Tablets administered orally without regard to food

DRUG

Bictegravir/emtricitabine/tenofovir alafenamide

Tablets administered orally without regard to food

DRUG

GS-1720/GS-4182 FDC

Tablets administered orally without regard to food

DRUG

Placebo to Match GS1720/GS-4182 FDC

Tablets administered orally without regard to food

Locations (39)

UAB 1917 Research Clinic

Birmingham, Alabama, United States

Pacific Oaks Medical Group

Beverly Hills, California, United States

Ruane Clinical Research Group

Los Angeles, California, United States

Mills Clinical Research

Los Angeles, California, United States

BIOS Clinical Research

Palm Springs, California, United States

UCSF Division of HIV, Infectious Diseases & Global Medicine

San Francisco, California, United States

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, United States

Georgetown University Medical Center

Washington D.C., District of Columbia, United States

Midland Florida Clinical Research Center, LLC

DeLand, Florida, United States

CAN Community Health

Fort Lauderdale, Florida, United States

Midway and Immunology Research Center

Ft. Pierce, Florida, United States

AIDS Healthcare Foundation - The Kinder Medical Group

Miami, Florida, United States

Floridian Clinical Research

Miami Lakes, Florida, United States

Orlando Immunology Center

Orlando, Florida, United States

CAN Community Health

Sarasota, Florida, United States

Triple O Research Institute, P.A.

West Palm Beach, Florida, United States

Metro Infectious Disease Consultants, P.L.L.C.

Decatur, Georgia, United States

Mercer University, Department of Internal Medicine

Macon, Georgia, United States

Chatham County Health Department

Savannah, Georgia, United States

Be Well Medical Center

Berkley, Michigan, United States

KC CARE Health Center

Kansas City, Missouri, United States

Saint Michael's Medical Center

Newark, New Jersey, United States

AXCES Research Group, LLC

Santa Fe, New Mexico, United States

NewYork-Presbyterian Queens

Flushing, New York, United States

NYU Langone Health Vaccine Center

New York, New York, United States

Rosedale Health and Wellness

Huntersville, North Carolina, United States

Central Texas Clinical Research

Austin, Texas, United States

St Hope Foundation, Inc.

Bellaire, Texas, United States

Prism Health North Texas, Oak Cliff Health Center

Dallas, Texas, United States

North Texas Infectious Diseases Consultants, PA

Dallas, Texas, United States

AXCES Research Group, LLC

El Paso, Texas, United States

Texas Centers for Infectious Disease Associates

Fort Worth, Texas, United States

The Crofoot Research Center, INC.

Houston, Texas, United States

DCOL Center for Clinical Research

Longview, Texas, United States

Peter Shalit, MD

Seattle, Washington, United States

Centro Ararat, Inc.

San Juan, PR, Puerto Rico

Clinical Research Puerto Rico

San Juan, PR, Puerto Rico

HOPE Clinical Research

San Juan, PR, Puerto Rico

Proyecto ACTC

San Juan, PR, Puerto Rico